Skip to content
Screener

EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.68B+68.1%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.19B+76.0%
Gilead Sciences logo
Gilead SciencesGILD
-$10.3B-501%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$125.93M+12.4%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$43.22M+30.4%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$46.23M-7.7%

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$1B+35.5%
Enterprise value$996.16M+31.8%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Calculated from Sana Biotechnology’s reported figures.

$48.6Mebit+
$2.4MDepreciation Depletion & Amortization
=-$46.22M

The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216769

FAQ

What is Sana Biotechnology's EBITDA?
Sana Biotechnology (SANA) reported EBITDA of -$46.22M in Q1 2026.
How has Sana Biotechnology's EBITDA changed year-over-year?
Sana Biotechnology's EBITDA increased by 1.6% year-over-year, from -$46.98M to -$46.22M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Sana Biotechnology's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude